1. Home
  2. ALAB vs UTHR Comparison

ALAB vs UTHR Comparison

Compare ALAB & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALAB
  • UTHR
  • Stock Information
  • Founded
  • ALAB 2017
  • UTHR 1996
  • Country
  • ALAB United States
  • UTHR United States
  • Employees
  • ALAB N/A
  • UTHR N/A
  • Industry
  • ALAB
  • UTHR Biotechnology: Pharmaceutical Preparations
  • Sector
  • ALAB
  • UTHR Health Care
  • Exchange
  • ALAB NYSE
  • UTHR Nasdaq
  • Market Cap
  • ALAB 16.1B
  • UTHR 14.4B
  • IPO Year
  • ALAB 2024
  • UTHR 1999
  • Fundamental
  • Price
  • ALAB $93.08
  • UTHR $290.75
  • Analyst Decision
  • ALAB Strong Buy
  • UTHR Buy
  • Analyst Count
  • ALAB 15
  • UTHR 13
  • Target Price
  • ALAB $97.50
  • UTHR $393.08
  • AVG Volume (30 Days)
  • ALAB 4.0M
  • UTHR 693.7K
  • Earning Date
  • ALAB 05-06-2025
  • UTHR 07-30-2025
  • Dividend Yield
  • ALAB N/A
  • UTHR N/A
  • EPS Growth
  • ALAB N/A
  • UTHR 18.86
  • EPS
  • ALAB 0.26
  • UTHR 25.10
  • Revenue
  • ALAB $490,474,000.00
  • UTHR $2,994,100,000.00
  • Revenue This Year
  • ALAB $80.73
  • UTHR $14.30
  • Revenue Next Year
  • ALAB $28.94
  • UTHR $6.32
  • P/E Ratio
  • ALAB $363.37
  • UTHR $11.58
  • Revenue Growth
  • ALAB 200.19
  • UTHR 19.84
  • 52 Week Low
  • ALAB $36.22
  • UTHR $266.98
  • 52 Week High
  • ALAB $147.39
  • UTHR $417.82
  • Technical
  • Relative Strength Index (RSI)
  • ALAB N/A
  • UTHR 42.82
  • Support Level
  • ALAB N/A
  • UTHR $282.89
  • Resistance Level
  • ALAB N/A
  • UTHR $329.85
  • Average True Range (ATR)
  • ALAB 0.00
  • UTHR 9.17
  • MACD
  • ALAB 0.00
  • UTHR -2.82
  • Stochastic Oscillator
  • ALAB 0.00
  • UTHR 27.45

About ALAB ASTERA LABS INC

Astera Labs Inc designs and delivers semiconductor-based connectivity solutions for cloud and AI infrastructure. Its Intelligent Connectivity Platform integrates semiconductor technology, microcontrollers, sensors, and software to enhance performance, scalability, and data management. The company offers products such as integrated circuits (ICs), boards, and modules, catering to hyperscalers and system OEMs. The company's solutions focus on data, network, and memory management in AI-driven platforms.

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.

Share on Social Networks: